• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 413464 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414249754 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414249754 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Ariad Pharmaceuticals Shares Climbing Higher, Up 4.8%

Published on Wed, 01/02/2013 - 11:28
By Robert Cotter

Ariad Pharmaceuticals (NASDAQ:ARIA) is a company whose shares are active, trading 4.8% higher to $20.10. The S&P is currently trading 1.8% higher to 1,452 and the Dow Jones Industrial Average is trading 1.8% higher to 13,339.

Ariad Pharmaceuticals share prices have moved between a 52-week high of $25.40 and a 52-week low of $12.26 and are now trading 64% above that low price at $20.10 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.7% while the 200-day MA has risen 0.5%.

Ariad Pharmaceuticals has overhead space with shares priced $20.10, or 30.4% below the average consensus analyst price target of $28.88. The stock should find resistance at its 50-day moving average (MA) of $21.57, as well as support at its 200-day MA of $19.27.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Shares of Travelers Rise Above Previous ...

Shares of Travelers (NYSE:TRV) traded today at $97.70, breaking its 52-week high. Appr ...

Shares of Transglobe Energy Fall to a Ne...

Transglobe Energy (NASDAQ:TGA) traded today at a new 52-week low of $4.66. So far toda ...

Shares of Teleflex Have Risen Above Prev...

Shares of Teleflex (NYSE:TFX) traded today at $111.56, breaking its 52-week high. Appr ...

Southwest Gas: 52-Week High Recently Ecl...

Southwest Gas (NYSE:SWX) traded today at a new 52-week high of $56.15. So far today ap ...

Shares of Southwestern Energy Have Falle...

Shares of Southwestern Energy (NYSE:SWN) traded at a new 52-week low today of $31.28. ...

Shares of Sovran Self Storage Rise to a ...

Shares of Sovran Self Storage (NYSE:SSS) traded today at $82.98, breaking its 52-week h ...

Recent 52-Week High Exceeded in Shares o...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.92. So far today approxi ...

Super Micro Computer: The Winning Streak...

Super Micro Computer (NASDAQ:SMCI) traded today at a new 52-week high of $31.00. This ...